Tompkins CNE, et al. - In order to assess whether opioid users would be willing to receive prolonged-release buprenorphine depot injections and to determine what issues may impact their interest, researchers conducted semi-structured qualitative interviews with patients who were using heroin daily and not receiving any treatment for opioid use (n=12), were prescribed daily oral buprenorphine (n=12), or were prescribed daily oral methadone (n=12). Greater choice and flexibility in opioid agonist medications seemed welcomed and acceptance and adherence to depot buprenorphine seemed higher if it helps reduce their illicit drug use and facilitates their recovery. Key factors impacting interest in buprenorphine depot injections were less contact with pharmacies and drug treatment services, effect on illicit drug use and recovery, effectiveness of treatment, duration and dosage of injections, clinical administration, and potential side effects.